secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001193125-25-050372
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio presents positive Phase 2a results for bempikibart in alopecia areata at AAD 2025
--------------------------------------------------------------------------------

- Bempikibart showed 16% mean SALT reduction at week 24 vs 2% placebo (p=0.045) in severe/very severe AA patients.
- Deepening responses observed post-dosing: 28% mean SALT reduction at week 36 in severe subset; two patients maintained response at week 55.
- Well-tolerated safety profile: no Grade 3+ related AEs, no related viral infections; PK and target engagement confirmed.
- OLE and SIGNAL-AA Part B (36-week dosing) to start 1H'25; Part B topline data expected 1H'26.
- All 12 responding patients maintained or improved hair growth post-treatment, median follow-up 41 weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312525050372/0001193125-25-050372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312525050372/d931400d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-050372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer